Fabrizio De Benedetti, M.D http://priligyes.com/revisiones.html ., Ph.D., Hermine I. Brunner, M.D., Nicolino Ruperto, M.D., M.P.H., Andrew Kenwright, B.Sc., Stephen Wright, M.D., Inmaculada Calvo, M.D., Ruben Cuttica, M.D., Angelo Ravelli, M.D., Rayfel Schneider, M.D., Patricia Woo, M.D., Ph.D., Carine Wouters, M.D., Ricardo Xavier, M.D., Lawrence Zemel, M.D., Eileen Baildam, M.D., Ruben Burgos-Vargas, M.D., Pavla Dolezalova, M.D., Stella M. Garay, M.D., Rosa Merino, M.D., Rik Joos, M.D., Alexei Grom, M.D., Ph.D., Nico Wulffraat, M.D., Zbigniew Zuber, M.D., Francesco Zulian, M.D., Daniel Lovell, M.D., M.P.H., and Alberto Martini, M.D.
Individuals with subtype B. All assays had been performed in duplicate. Statistical Analysis On the basis of data from the CASCADE study,24 we calculated that people would need to enroll 360 patients in order to provide 90 percent capacity to detect a relative decrease in the risk of progression to the initial primary end stage of 50 percent with 48-week ART and 25 percent with 12-week ART, as compared with standard care, at a significance level of 5 percent. We assumed a recruitment period of 18 months, at the least 3.5 years of follow-up, and a 10 percent rate of loss to follow-up.